Skip to content
OpenCapital
Get started

Pfizer PFE All other Oncology — Revenues:

Other product segments

Eliquis
$2.17B+12.6%
Prevnar Family
$1.69B+1.8%
Vyndaqel family
$1.6B+7.8%
Ibrance
$1.01B+3.2%
All Other Hospital and Biosimilars
$953M—
All other Primary Care
$654M+7.4%
Padcev
$591M+38.7%
All other Specialty Care
$579M+19.1%
Xtandi
$444M-3.1%
Oncology Biosimilars
$409M+54.9%
Royalty
$396M+28.6%
Nurtec ODT/Vydura
$353M+42.3%
Lorbrena
$305M+37.4%
Pfizer CentreOne
$289M+5.9%
Comirnaty
$232M-58.9%
Paxlovid
$219M-69.9%
Inlyta
$214M-2.3%
Sulperazon (Outside the U.S. and Canada)
$199M+21.3%
Adcetris
$190M-12.8%
Inflectra
$182M—
Abrysvo
$180M+37.4%
Xeljanz
$180M+40.6%
Braftovi/Mektovi
$174M+27.9%
Zavicefta (Outside the U.S. and Canada)
$150M+11.1%
Enbrel (Outside the U.S. and Canada)
$138M-1.4%
Bosulif
$129M-14.6%
Octagam
$122M—
Tukysa
$122M+19.6%
Zithromax
$112M-29.1%
Orgovyx
$109M—
Genotropin
$93M—
FSME-IMMUN/TicoVac
$81M—
Elrexfio
$80M+33.3%
Cibinqo
$76M+31.0%
Talzenna
$50M+25.0%
Tivdak
$33M0.0%

Similar metrics at other companies

Eli Lilly logo
LLYOther oncology — Revenue
$966M+22.4%
Johnson & Johnson logo
JNJOther Oncology — Sales to customers (Note 9)
$192M-10.3%
Arcus Biosciences logo
RCUSOther — Total revenues
$2M—
Eli Lilly logo
LLYOncology — Revenue
$2.27B+16.4%
BillionToOne, Inc. logo
BLLNOncology — Revenue
$10.72M+392%
Jazz Pharmaceuticals logo
JAZZOncology — Revenue from Contract with Customer, Excluding Assessed Tax
$333.4M+45.3%

Other financials

Income statement

See full
Revenue$14.5B+5.4%
Gross profit$10.9B+0.3%
Net income$2.7B-9.4%
EPS (diluted)$0.47-9.6%

Balance sheet

See full
Cash & equivalents$1.8B+18.8%
Total debt$64.4B+4.9%
Total equity$90.1B-0.3%
Total assets$207.62B-0.2%

Cash flow

See full
Operating cash flow$2.6B+12.0%
CapEx$436.0M-22.7%
Free cash flow$2.2B+23.0%

Valuation

See full
Market cap$138.21B-3.7%
Enterprise value$200.88B-1.3%
P/E11.4×—
P/S2.2×-0.1×

Profitability

See full
Gross margin73.5%+1.2pp
Net margin15.7%—
FCF margin18%+8.8pp

Returns & leverage

See full
Return on equity10.6%—
Debt / equity0.7×0.0×
Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's all other oncology — revenues:.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pfizer's all other oncology — revenues:?
Pfizer (PFE) reported all other oncology — revenues: of $376M in Q1 2026.
How has Pfizer's all other oncology — revenues: changed year-over-year?
Pfizer's all other oncology — revenues: decreased by 0.3% year-over-year, from $377M to $376M.
What is the long-term trend for Pfizer's all other oncology — revenues:?
Over 4 years (2021 to 2025), Pfizer's all other oncology — revenues: has grown at a 54.0% compound annual growth rate (CAGR), from $237M to $1.33B.
What does all other oncology — revenues: mean?
This metric represents the total net sales generated by the company's secondary or emerging oncology product portfolio, excluding primary blockbuster cancer therapies. It captures revenue streams from niche, specialized, or early-stage oncology treatments that contribute to the company's broader cancer care strategy. Monitoring this segment helps investors assess the company's ability to diversify its oncology pipeline and identify future growth drivers beyond established flagship products.